Prognostic relevance of systematic lymph node dissection in gastric carcinoma

1993 ◽  
Vol 80 (8) ◽  
pp. 1015-1018 ◽  
Author(s):  
J. R. Siewert ◽  
K. Böttcher ◽  
J. D. Roder ◽  
R. Busch ◽  
P. Hermanek ◽  
...  
Keyword(s):  
Lymph Node ◽  
Gastric Carcinoma ◽  
Lymph Node Dissection ◽  
Node Dissection ◽  
Prognostic Relevance ◽  
Systematic Lymph Node Dissection

Prognostic relevance of systematic lymph node dissection in gastric carcinoma

1994 ◽  
Vol 81 (2) ◽  
pp. 315-316 ◽  
Author(s):  
W. J. Lee ◽  
J. R. Siewert ◽  
J. D. Roder ◽  
K. Böttcher ◽  
P. Hermanek
Keyword(s):  
Lymph Node ◽  
Gastric Carcinoma ◽  
Lymph Node Dissection ◽  
Node Dissection ◽  
Prognostic Relevance ◽  
Systematic Lymph Node Dissection

scholarly journals Survival after resection of gastric cancer and prognostic relevance of systematic lymph node dissection: Twenty years experience in Taiwan

1995 ◽  
Vol 19 (5) ◽  
pp. 707-713 ◽  
Author(s):  
Wei-Jei Lee ◽  
Wen-Chung Lee ◽  
Shyh-Jinn Houng ◽  
Chia-Tung Shun ◽  
Ren-Long Houng ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Lymph Node ◽  
Lymph Node Dissection ◽  
Node Dissection ◽  
Prognostic Relevance ◽  
Systematic Lymph Node Dissection

Prognostic relevance of systemic lymph node dissection in gastric carcinoma

1995 ◽  
Vol 82 (9) ◽  
pp. 1287-1289 ◽  
Author(s):  
D. H. Roukos ◽  
G. Baltogiannis ◽  
D. Cassioumis ◽  
J. R. Siewert ◽  
J. D. Roder
Keyword(s):  
Lymph Node ◽  
Gastric Carcinoma ◽  
Lymph Node Dissection ◽  
Node Dissection ◽  
Prognostic Relevance

scholarly journals Clinical Impact of Lymphadenectomy after Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: A Review of Available Data

2021 ◽  
Vol 10 (2) ◽  
pp. 334
Author(s):  
Stephanie Seidler ◽  
Meriem Koual ◽  
Guillaume Achen ◽  
Enrica Bentivegna ◽  
Laure Fournier ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Lymph Node ◽  
Neoadjuvant Chemotherapy ◽  
Epithelial Ovarian Cancer ◽  
Lymph Node Dissection ◽  
Prospective Trial ◽  
Node Dissection ◽  
Advanced Epithelial Ovarian Cancer ◽  
The Impact ◽  
Systematic Lymph Node Dissection

Recent robust data allow for omitting lymph node dissection for patients with advanced epithelial ovarian cancer (EOC) and without any suspicion of lymph node metastases, without compromising recurrence-free survival (RFS), nor overall survival (OS), in the setting of primary surgical treatment. Evidence supporting the same postulate for patients undergoing complete cytoreductive surgery after neoadjuvant chemotherapy (NACT) is lacking. Throughout a systematic literature review, the aim of our study was to evaluate the impact of lymph node dissection in patients undergoing surgery for advanced-stage EOC after NACT. A total of 1094 patients, included in six retrospective series, underwent either systematic, selective or no lymph node dissection. Only one study reveals a positive effect of lymphadenectomy on OS, and two on RFS. The four remaining series fail to demonstrate any beneficial effect on survival, neither for RFS nor OS. All of them highlight the higher peri- and post-operative complication rate associated with systematic lymph node dissection. Despite heterogeneity in the design of the studies included, there seems to be a trend showing no improvement on OS for systematic lymph node dissection in node negative patients. A well-conducted prospective trial is mandatory to evaluate this matter.

scholarly journals Effect of Lymphadenectomy on Survival in Early-Stage Type II Endometrial Carcinoma and Carcinosarcoma

2020 ◽  
Vol 2020 ◽  
pp. 1-6 ◽  
Author(s):  
Dogan Vatansever ◽  
Hamdullah Sozen ◽  
Gulcin Sahin Ersoy ◽  
Burak Giray ◽  
Samet Topuz ◽  
...  
Keyword(s):  
Lymph Node ◽  
Endometrial Carcinoma ◽  
Lymph Node Dissection ◽  
Early Stage ◽  
Hazard Ratio ◽  
Type Ii ◽  
Paraaortic Lymph Node ◽  
Node Dissection ◽  
Paraaortic Lymph Node Dissection ◽  
Systematic Lymph Node Dissection

Purpose. We aimed to investigate whether systematic pelvic and paraaortic lymph node dissection delivers any survival advantage in a subgroup of patients with type II endometrial carcinoma and carcinosarcoma. Methods. We evaluated 135 patients with clinically early-stage (Stage I-II) type II endometrial carcinoma and carcinosarcoma who underwent systematic pelvic and paraaortic lymph node dissection or who did not undergo any lymph node dissection. Results. Overall survival (OS) and recurrence-free survivals (RFS) were significantly longer in the systematic lymph node dissection group (hazard ratio 0.28, 95% CI 0.13–0.62 p=0.002 for OS and hazard ratio 0.31, 95% CI 0.14–0.69 p=0.004 for RFS). Multivariate analysis showed that lymph node dissection, age, lymph node metastasis, and adjuvant therapy were independent prognostic variables of OS and RFS. Conclusions. Systematic pelvic and paraaortic lymph node dissection independently and significantly prolongs the survival of patients with early-stage type II endometrial carcinoma and carcinosarcoma.

Sign in / Sign up

Export Citation Format

Share Document